Credit Suisse Ag Genetic Technologies LTD Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.0 - $0.01 $0 - $250	-25,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.0 - $0.0 $0 - $0	25,000 New	25,000 $49,000
Q1 2021 May 14, 2021	SELL	$0.0 - $0.01 $0 - $208	-20,836 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$0.0 - $0.0 $0 - $0	20,836 New	20,836 $75,000

Ticker GENE
Exchange OTC
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 15,389,900
Market Cap $21.1M
Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.